MANKIND

Mankind Pharma Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 26 Oct, 08:59 pm IST Q2 FY27 (Sep ’26)Consolidated₹ crores

Revenue

4,337.86

▲ 17.3% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

1,171.25

▲ 27.1% vs Q2 FY26

Net profit

716.12

▲ 37.7% vs Q2 FY26

EPS (₹)

17.23

▲ 39.1% vs Q2 FY26

Operating margin

27.0%

+210 bps vs Q2 FY26

Net margin

16.5%

+240 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+17% vs Q2 FY26 · +8% vs Q1 FY27

Profit+38% vs Q2 FY26 · +25% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	4,337.86	4,030.59	▲ 7.6%	3,697.16	▲ 17.3%
Other income	94.85	45	▲ 110.8%	91.87	▲ 3.2%
Total income	4,432.71	4,075.59	▲ 8.8%	3,789.03	▲ 17.0%
Total expenses	3,507.28	3,310.08	▲ 6.0%	3,167.33	▲ 10.7%
Operating profit (EBITDA)*	1,171.25	1,056.19	▲ 10.9%	921.33	▲ 27.1%
Profit before tax	925.43	765.51	▲ 20.9%	621.7	▲ 48.9%
Tax expense	212.99	195.36	▲ 9.0%	103.84	▲ 105.1%
Net profit	716.12	574.09	▲ 24.7%	520.18	▲ 37.7%
EPS (₹)	17.23	13.76	▲ 25.2%	12.39	▲ 39.1%
Operating margin	27.0%	26.2%	+80 bps	24.9%	+210 bps
Net margin	16.5%	14.2%	+230 bps	14.1%	+240 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ crores except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Mankind Pharma results, dividends & filings ›

Other results filed 26 Oct

NAZARA Nazara Technologies Limited›LEAPIND LEAP India Limited›PAYTM One 97 Communications Limited›SURANASOL Surana Solar Limited›WEWORK WeWork India Management Limited›DEEPA Deepa Jewellers Limited›SUNTECK Sunteck Realty Limited›SMCGLOBAL SMC Global Securities Limited›AEQUS Aequs Limited›PARACABLES Paramount Communications Limited›JBMA JBM Auto Limited›PNGSREVA PNGS Reva Diamond Jewellery Limited›

Today's results ›

MANKIND PHARMA Q2 FY27 ; NET PROFIT UP 38% AT ₹716 CR (YOY), UP 25% (QOQ)

REVENUE UP 17% AT ₹4,338 CR (YOY), UP 8% (QOQ)

EBITDA UP 27% AT ₹1,171 CR (YOY), UP 11% (QOQ)

MARGINS AT 27.0% VS 24.9% (YOY), 26.2% (QOQ)

https://resultkal.com/r/mankind-2026-10-26
Source: NSE filing · not investment advice

FAQ

When did Mankind Pharma announce Q2 FY27 results?

Mankind Pharma filed its results on NSE on 26 Oct, 08:59 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Mankind Pharma figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← MANKIND overview